2Hamilton LC,Vojnovic I,Warner TD.A771726,the activemetabolite of leflunomide,drectly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.Br J Pharmacol,1999;127(7):1589
3Alldred A,Emery P.Leflunomide:a novel D MARD for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2001;2 (1):125
4Jankovic V,Samardzic T,Stosic Grujicic S,et al.Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.Cell Immunol,2000;199(2):73
5Kraan MC,de Koster BM,Elferink JG,et al.Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis:findings in a prospective,randomized,double-blind clinical trial in fifteen patients.Arthritis Rheum,2000;43(7):1488
6Herrmann ML,Schleyerbach R,Kirschbaum BJ.Leflunomide:an immun-omodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.Immunophar macology,2000;47(2~3):273
7Mizushima Y,Amano Y,Kitagawa H,et al.Oral administration of leflunomide (H WA486)results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.J Pharmacol Exp Ther,1999;288(2):849
8Xiao F,Lv SF,Xu SY,et al.Leflunomide a new disease-modifying drugs for treating active rheumatoid arthritis in Phase Ⅱ methotrexatecontrolled clinical trial.Chinese Medcine,2001;in press.